Truist Financial Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM - Free Report) had its target price boosted by Truist Financial from $260.00 to $290.00 in a research report report published on Monday morning,Benzinga reports. They currently have a hold rating on the insurance provider's stock.

A number of other research analysts have also issued reports on the stock. Leerink Partnrs lowered shares of Humana from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 2nd. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $395.00 price target on shares of Humana in a research note on Tuesday, October 1st. Jefferies Financial Group cut shares of Humana from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Royal Bank of Canada lowered their target price on Humana from $400.00 to $265.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Finally, Stephens reiterated an "equal weight" rating and issued a $250.00 price target on shares of Humana in a research report on Wednesday, October 9th. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $302.00.

Humana Price Performance

Shares of HUM traded up $1.07 during mid-day trading on Monday, reaching $263.54. The company had a trading volume of 1,736,242 shares, compared to its average volume of 1,329,547. The company has a market capitalization of $31.73 billion, a price-to-earnings ratio of 23.34, a P/E/G ratio of 2.12 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company's 50 day simple moving average is $272.60 and its 200 day simple moving average is $313.45. Humana has a 1-year low of $213.31 and a 1-year high of $464.38.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts' consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to analysts' expectations of $28.66 billion. Analysts expect that Humana will post 16.14 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date is Tuesday, December 31st. Humana's payout ratio is 31.36%.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HUM. Nordea Investment Management AB boosted its holdings in Humana by 6.6% during the 4th quarter. Nordea Investment Management AB now owns 9,679 shares of the insurance provider's stock worth $2,487,000 after acquiring an additional 602 shares during the last quarter. Central Pacific Bank Trust Division grew its position in Humana by 110.7% in the 4th quarter. Central Pacific Bank Trust Division now owns 2,950 shares of the insurance provider's stock worth $748,000 after purchasing an additional 1,550 shares in the last quarter. Everence Capital Management Inc. increased its stake in Humana by 57.5% in the 4th quarter. Everence Capital Management Inc. now owns 5,530 shares of the insurance provider's stock valued at $1,403,000 after buying an additional 2,020 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Humana by 41.0% during the 4th quarter. GAMMA Investing LLC now owns 1,906 shares of the insurance provider's stock worth $484,000 after buying an additional 554 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in shares of Humana by 15.5% in the 4th quarter. Versant Capital Management Inc now owns 387 shares of the insurance provider's stock worth $98,000 after buying an additional 52 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.